Kyntra Bio (NASDAQ:KYNB) Research Coverage Started at Maxim Group

Maxim Group assumed coverage on shares of Kyntra Bio (NASDAQ:KYNB) in a report released on Tuesday, Marketbeat reports. The brokerage issued a buy rating and a $35.00 target price on the stock.

Other equities research analysts have also issued reports about the stock. Lake Street Capital initiated coverage on shares of Kyntra Bio in a research report on Thursday, September 17th. They issued a “buy” rating and a $41.00 price objective on the stock. HC Wainwright restated a “buy” rating and set a $43.00 target price on shares of Kyntra Bio in a report on Tuesday, September 1st. Oppenheimer initiated coverage on shares of Kyntra Bio in a report on Monday, July 6th. They set an “outperform” rating and a $35.00 target price for the company. Finally, Weiss Ratings cut shares of Kyntra Bio from a “sell (d+)” rating to a “sell (d)” rating in a research report on Friday, October 9th. Five research analysts have rated the stock with a Buy rating and two have issued a Sell rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus price target of $36.80.

Kyntra Bio Stock Performance

Shares of KYNB stock opened at $5.36 on Tuesday. Kyntra Bio has a fifty-two week low of $5.34 and a fifty-two week high of $11.65. The business has a fifty day simple moving average of $7.20 and a 200-day simple moving average of $7.11.

Hedge Funds Weigh In On Kyntra Bio

A hedge fund recently bought a new stake in Kyntra Bio stock. ADAR1 Capital Management LLC acquired a new stake in shares of Kyntra Bio Inc (NASDAQ:KYNB) in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund acquired 10,469 shares of the company’s stock, valued at approximately $71,000. ADAR1 Capital Management LLC owned 0.26% of Kyntra Bio as of its most recent SEC filing. 72.71% of the stock is currently owned by institutional investors and hedge funds.

Kyntra Bio Company Profile

FibroGen, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States, Europe, China, and Japan; and in Phase II/III development in China for anemia associated with myelodysplastic syndromes.